title: Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
abstract: BACKGROUND
  The ongoing phase IIb POWER 1 (TMC114-C213) trial is designed to assess efficacy and safety of the protease inhibitor (PI) TMC114 (darunavir) in treatment-experienced HIV-1-infected patients.
  
  
  METHODS
  This randomized, partially blinded, 24-week dose-finding study compared efficacy and safety of four doses of TMC114 plus low-dose ritonavir (TMC114/r) with investigator-selected control PI(s) (CPI[s]).
  
  
  METHODS
  Patients with one or more primary PI mutation and HIV RNA > 1000 copies/ml received optimized background therapy, plus TMC114/r 400/100 mg once daily, 800/100 mg once daily, 400/100 mg twice daily or 600/100 mg twice daily, or CPI(s). The primary endpoint (intent-to-treat) compared proportions of patients achieving viral load reduction >or= 1.0 log10 copies/ml from baseline.
  
  
  RESULTS
  In total, 318 patients were treated. Baseline mean viral load was 4.48 log10 copies/ml; median CD4 cell count was 179 cells/microl. In the CPI arm 62% of patients discontinued (virological failure: 54%); 10% of TMC114/r patients discontinued. More TMC114/r (69-77%) than CPI patients (25%) reached the primary endpoint (P < 0.001); 43-53% of TMC114/r patients and 18% of the CPI arm achieved viral load < 50 copies/ml (P < 0.001). TMC114/r demonstrated greater mean CD4 cell count increases versus CPI(s) (68-124 versus 20 cells/microl; P < 0.05). TMC114/r 600/100 mg twice daily demonstrated the highest virological and immunological responses. Adverse event incidence was similar between treatments; headache and diarrhoea were more common with CPI(s).
  
  
  CONCLUSIONS
  TMC114/r demonstrated statistically higher 24-week virological response rates and CD4 cell count increases than CPI(s). TMC114/r 600/100 mg twice daily has received regulatory approval in treatment-experienced patients.
authors.affiliation: Hôpital Pitié-Salpêtrière, Paris, France. christine.katlama@psl.ap-hop-paris.fr
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Roberto
authors.initials: R
authors.lastname: Esposito
authors.forename: Jose M
authors.initials: JM
authors.lastname: Gatell
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Goffard
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
authors.forename: Anton
authors.initials: A
authors.lastname: Pozniak
authors.forename: Jurgen
authors.initials: J
authors.lastname: Rockstroh
authors.forename: Albrecht
authors.initials: A
authors.lastname: Stoehr
authors.forename: Norbert
authors.initials: N
authors.lastname: Vetter
authors.forename: Patrick
authors.initials: P
authors.lastname: Yeni
authors.forename: Wim
authors.initials: W
authors.lastname: Parys
authors.forename: Tony
authors.initials: T
authors.lastname: Vangeneugden
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D000069454:Darunavir; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir